2023 World Conference on Lung Cancer (Posters)-EP12.01. Clinical Features and Progression Free Survival of Lung Adenocarcinoma Patients with EGFR sensitizing mutations with Dose Reduction of Afatinib

EP12.01. Clinical Features and Progression Free Survival of Lung Adenocarcinoma Patients with EGFR sensitizing mutations with Dose Reduction of Afatinib - PDF(Slides)

Back to course

Pdf Summary

This study aimed to evaluate the clinical features and progression-free survival (PFS) of lung adenocarcinoma patients with EGFR sensitizing mutations who underwent dose reduction of the medication, afatinib. Afatinib is a standard therapy for non-small cell lung cancer (NSCLC) with EGFR sensitizing mutations, and dose reduction is often necessary to manage adverse events.<br /><br />The study was conducted on 86 patients with EGFR sensitizing mutation-positive lung adenocarcinoma who received afatinib as a first-line treatment under the Universal Health Coverage scheme at Persahabatan Hospital in Indonesia. The patients were retrospectively analyzed to determine the impact of dose reduction on PFS.<br /><br />The results showed that patients who underwent dose reduction of afatinib had similar median PFS compared to those who did not have dose reduction. The median PFS for patients receiving 40mg/day, 30mg/day, and 20mg/day of afatinib were 12 months, 15 months, and 14 months, respectively. The difference in PFS between the dose reduction groups was not statistically significant.<br /><br />The study also found that dose reduction of afatinib was more common in female patients, those who were 65 years old or older, those with deletion exon 19 mutation, and those with a performance status of 0-1. However, there was no significant difference between patients receiving and not receiving dose reduction in terms of clinical characteristics.<br /><br />Overall, the study concluded that dose reduction of afatinib provides similar clinical benefits as non-dose reductions for lung adenocarcinoma patients with EGFR sensitizing mutations. Adverse events, such as diarrhea, paronychia, skin rash, and stomatitis, were the main reasons for dose reduction.<br /><br />In summary, reducing the dose of afatinib can effectively manage adverse events without compromising the benefits of the medication for lung adenocarcinoma patients with EGFR sensitizing mutations. This study provides real-world evidence for the efficacy of dose reduction in these patients.

Asset Subtitle

Widya Angasreni

Meta Tag

Speaker Widya Angasreni

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

lung adenocarcinoma

EGFR sensitizing mutations

afatinib

dose reduction

progression-free survival

non-small cell lung cancer

clinical features

Universal Health Coverage scheme

Persahabatan Hospital

adverse events